blue cross blue shield semaglutide IBX parent company posts $239M

Add cooked lentils and diced cucumber to the kale

It just made our Ro In-House team more efficient and allowed them to spend more time deciding what actually mattered

doi: 10.1097/HCO.0000000000000673 17 FerrarioCMStrawnWB

Quick Answer: The exact mechanism by which GLP-1 receptor agonists might cause pancreatitis remains unproven, though proposed pathways include indirect effects through increased gallbladder disease risk rather than direct pancreatic toxicity

Trial participant reports While not systematic data, reports from TRIUMPH trial participants provide additional context: Evidence: Community-reported One TRIUMPH-1 participant reported losing 30.6% of body weight (approximately 75 pounds) after one year on the trial, going from XL/2XL shirts to medium and fitting into size 32 pants for the first time in 20 years The same participant reported cholesterol down 30-33%, triglycerides down 70%, blood pressure normalized, fatty liver disease resolved (confirmed by CT scan), and asthma symptoms eliminated These individual results are consistent with the upper range of clinical trial outcomes and should not be taken as typical Beyond Weight Loss: Other Results TRIUMPH-4 measured outcomes beyond the scale: Cardiovascular markers Knee osteoarthritis outcomes (TRIUMPH-4 specific) Liver fat (Phase 2 sub-study) A sub-study of the Phase 2 trial measured liver fat by MRI and found reductions of up to 82.4% at the highest dose among the strongest liver fat reduction results for any drug in development